Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Multi-Center, Open Label Trial of the Safety and Efficacy of Fostamatinib in Patients With Relapsed/Refractory B-Cell Lymphoma

NCT00446095 is registered in ClinicalTrials.gov with Rigel Pharmaceuticals as lead sponsor.

NCT NCT00446095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00446095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Multi-Center, Open Label Trial of the Safety and Efficacy of Fostamatinib in Patients With Relapsed/Refractory B-Cell Lymphoma
Lead sponsor
Rigel Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2007
Completion date
October 31, 2010
Enrollment
81 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma